News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cascadian Therapeutics (ONTY) Strengthens Management Team With Key Hires, Monique M. Greer And Marc C. Chamberlain, M.D.



11/28/2016 7:10:07 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

SEATTLE, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the Company strengthened its leadership team with the appointment of Monique M. Greer as Senior Vice President, Investor Relations and Corporate Communications, and Marc C. Chamberlain, M.D., as Medical Director. Ms. Greer will be a member of the Company’s executive committee and will report to Scott D. Myers, Chief Executive Officer of Cascadian Therapeutics. Ms. Greer will have responsibility for external communications, including investor relations, media and digital communications, and advocacy relations. Dr. Chamberlain, a neuro-oncologist, will serve as Medical Director reporting to Dr. Luke Walker, Vice President, Clinical Development. Dr. Chamberlain will be focused on applying his expertise in understanding and treating brain tumors and metastatic diseases in the Central Nervous System (CNS) to Cascadian’s lead late-stage development program evaluating tucatinib, formerly known as ONT-380, in HER2-positive metastatic breast cancer.

“We are pleased to have these talented leaders join Cascadian at this important time in our corporate development,” said Scott D. Myers, Chief Executive Officer. “We believe that their proven leadership and skill sets will benefit us as we continue to advance tucatinib, our lead program for the treatment of patients with HER2-positive breast cancer in patients with or without brain metastases, through late-stage clinical development and towards commercialization.”

Monique M. Greer
Ms. Greer, a veteran biopharmaceutical executive, joins Cascadian Therapeutics with over 20 years of experience driving communications strategies and initiatives. She has played an active role in several successful financing rounds and helped launch multiple drugs in the U.S. and Europe. Ms. Greer was most recently Senior Vice President of Corporate Communications and Investor Relations at CTI BioPharma Corp., where she led the company’s corporate, investor and product communications. Ms. Greer also served in similar functions at Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals); WCG, a global communications agency; Dendreon Corporation and Heska Corporation.

Marc C. Chamberlain, M.D.
Dr. Chamberlain was most recently Professor of Neurology and Neurological Surgery at the University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance in Seattle, Washington. Dr. Chamberlain has developed many of the methods used today in evaluating and managing neoplastic meningitis. Dr. Chamberlain has focused increasingly on clinical trials for primary brain tumors, hoping to achieve new and better therapies. He has published his work in more than 350 scientific papers in peer-reviewed publications. Dr. Chamberlain received his medical degree in from Columbia University, College of Physicians and Surgeons in New York.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, also known as ONT-380, is an oral, selective small molecule HER2 inhibitor. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information and to sign up for email alerts or RSS feeds, please visit www.cascadianrx.com.

Contacts: Monique Greer Cascadian Therapeutics 206-801-2107 mgreer@cascadianrx.com Media Contact: Brad Miles BMC Communications 917-570-7340 bmiles@bmccommunications.com

Primary Logo


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES